Century Therapeutics (IPSC) EBIT (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of EBIT data on file, last reported at -$23.7 million in Q1 2026.

• On a quarterly basis, EBIT fell 131.93% year-over-year to -$23.7 million in Q1 2026; TTM through Mar 2026 was -$115.1 million, a 252.58% decrease from a year earlier, with the FY2025 full-year figure at -$17.3 million, up 87.5% from the prior year.
• EBIT for Q1 2026 stood at -$23.7 million, down from -$20.7 million in the prior quarter.
• Over the last five years, EBIT for IPSC reached as high as $74.2 million in Q1 2025 and fell as low as -$43.8 million in Q4 2023.
• Historically, EBIT has averaged -$27.0 million across 5 years, with a median of -$34.7 million in 2025.
• Across the five-year window, EBIT jumped 336.92% in 2025 and tumbled 131.93% in 2026, its largest moves.
• Year by year, EBIT stood at -$33.3 million in 2022, then sank by 31.39% to -$43.8 million in 2023, then grew by 14.8% to -$37.3 million in 2024, then soared by 44.61% to -$20.7 million in 2025, then decreased by 14.69% to -$23.7 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$23.7 million in Q1 2026, -$20.7 million in Q4 2025, and -$36.1 million in Q3 2025.